Aldosterone synthase inhibitors – a potentially new class of antihypertensive drugs
Laffin, Luke
( Cleveland Clinic Foundation
, Cleveland
, Ohio
, United States
)
Luther, James
( VANDERBILT UNIV MED CTR
, Nashville
, Tennessee
, United States
)
Kline, Gregory
( University of Calgary
, Calgary
, Alberta
, Canada
)
Author Disclosures:
Luke Laffin:DO have relevant financial relationships
;
Research Funding (PI or named investigator):Mineralys:Active (exists now)
; Consultant:Ripple Medical:Active (exists now)
; Consultant:Medtronic:Active (exists now)
; Consultant:Recor:Active (exists now)
; Royalties/Patent Beneficiary:Elsevier:Active (exists now)
; Research Funding (PI or named investigator):Eli Lilly:Active (exists now)
; Advisor:Novartis:Active (exists now)
; Advisor:Crispr Theapeutics:Active (exists now)
; Research Funding (PI or named investigator):Kardigan:Active (exists now)
; Consultant:Astrazeneca:Active (exists now)
; Research Funding (PI or named investigator):Arrowhead:Active (exists now)
| James Luther:DO have relevant financial relationships
;
Consultant:Mineralys:Active (exists now)
; Other (please indicate in the box next to the company name):AHA (editorial board):Active (exists now)
; Research Funding (PI or named investigator):NIH:Active (exists now)
; Consultant:Novo Nordisk:Active (exists now)
| Gregory Kline:No Answer